# The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

> **NCT00165815** · PHASE3 · COMPLETED · sponsor: **Eisai Limited**

## Conditions studied

- Dementia With Parkinson's Disease

## Interventions

- **DRUG:** ARICEPT

## Key facts

- **NCT ID:** NCT00165815
- **Lead sponsor:** Eisai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165815, "The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00165815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*